Ana sayfa
Piyasalar
Grafikler ve fikirler
Algo
Haberler
Store
Aracı kurumlar
İndir
Ekonomik Takvim
Alım-satım sinyalleri
Web Terminali
Arama yapmak için
/
tuşuna basın: @kullanıcı, $sembol, ...
Ara
Giriş yap
Hesap oluştur
Türkçe
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
KRYS
#874
Krystal Biotech, Inc. Common Stock
275.640
0
+1.85%
Sektör:
Baz:
Kar para birimi:
Günlük aralık
Yıllık aralık
Günlük değişim
+1.85%
Aylık değişim
-0.92%
6 aylık değişim
+47.30%
Yıllık değişim
+47.30%
Önceki kapanış
270.630
0
Open
275.640
0
Bid
Ask
Low
275.640
0
High
275.640
0
Hacim
67
Piyasalar
ABD hisse senetleri
Sağlık hizmetleri
KRYS
Open full chart
Financials
Overview
Rapor
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
TTM
Key stats
Total common shares outstanding
28.76 M
28.81 M
28.9 M
28.94 M
29 M
29.23 M
—
Valuation ratios
Enterprise value
4.86 B
4.17 B
4.9 B
3.62 B
4.73 B
6.71 B
19.96 B
Price to earnings ratio
87.51
52.22
43.24
27.88
26.43
36.04
133.59
Price to sales ratio
22.01
16.04
16.06
11.39
14.1
18.98
60.54
Price to cash flow ratio
68.81
37.75
38.72
20.94
29.86
36.76
126.28
Price to book ratio
1.6
4.92
1.46
1.06
1.28
6.05
9.86
Enterprise value to EBITDA ratio
—
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.03
0.04
0.03
0.03
0.06
0.04
0.17
Return on equity %
0.03
0.05
0.04
0.04
0.07
0.04
0.19
Return on invested capital %
22.21
25.02
26.31
28.8
35.93
35.83
126.87
Gross margin %
100
100
100
100
100
100
400
Operating margin %
26.76
30.69
41.02
40.93
42.3
41.49
165.75
EBITDA margin %
—
—
—
—
—
—
—
Net margin %
32.42
49.9
40.52
39.91
81.15
47.99
209.57
Liquidity ratios
Quick ratio
7.76
7.02
9.27
9.33
9.73
9.56
37.88
Current ratio
7.97
7.28
9.65
9.68
10.14
9.95
39.42
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0.09
0.09
0.08
0.09
0.08
0.08
0.34
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
1.97
1.78
1.04
1.77
1.33
2.59
6.73
EBIT per share
—
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
—
Cash per share
19.67
20.09
20.65
22.93
24.51
27.64
95.72
Net current asset value per share
23.85
24.95
25.67
28.28
31.03
34.21
119.19
Tangible book value per share
29.62
31.82
32.96
34.98
38.14
40.72
146.81
Working capital per share
20.86
21.52
23.01
25.36
27.97
30.77
107.11
Book value per share
29.62
31.82
32.96
34.98
38.14
40.72
146.81
Haberler
Krystal Biotech yöneticisi Janney 10,1 milyon dolarlık hisse sattı
Krystal Biotech director Janney sells shares worth $10.1 million
Krystal Biotech yöneticisi Rossi 4,95 milyon dolar değerinde hisse sattı
Krystal Biotech (KRYS) director Rossi sells shares worth $4.95 million
AI Play SPX Leads 17 Top Performers Onto Best Stock Screens Like IBD 50, Stock Spotlight, More
Krystal Biotech Q4 Earnings Beat Estimates, Revenues Miss Mark
Dow Jones Futures Fall After Market Reverses Higher; Meta Deal Lifts Nvidia, Hits AI Rivals
Krystal Biotech, Inc. (KRYS) Q4 2025 Earnings Call Transcript
Krystal Biotech hisseleri 296,78 dolar ile tüm zamanların en yüksek seviyesine ulaştı
Krystal Biotech stock reaches all-time high at 296.78 USD
Krystal Biotech 2025 4. Çeyrek: VYJUVEK gelir artışını sürüklüyor, ilaç hattı ilerliyor
Krystal Biotech Q4 2025 slides: VYJUVEK drives revenue growth, pipeline advances